

Phytotherapeutika in der Behandlung von Menopause-Beschwerden

Dr. med. Matthias Kraft
Zürichstrasse 52
8134 Adliswil | Schweiz
m.kraft@swissmedicalclinic.ch
www.swissmedicalclinic.ch

Dr. Olaf Katzler
Schäferkampsallee 34
20357 Hamburg | Deutschland
katzler@mammazentrum-hamburg.de
www.mammazentrum-hamburg.de

Prof. Dr. Dr. med. Ben Pfeifer
Aeskulap International AG
Grendel 2
6004 Luzern | Schweiz
bpf@eskulap-international.org

Literatur

- [1] Studd, J. Ovariectomy for menstrual madness and premenstrual syndrome – 19th century history and lessons for current practice. *Gynecological Endocrinology* 2006; 22: 411–415
- [2] Skae F. Climacteric Insanity in Women. *Journal of Mental Science*. 1865; 11:275–278
- [3] Wren BG. The history and politics of menopause. In: Panay N, Briggs P, Kovacs G, eds. *Managing the Menopause: 21st Century Solutions*. Cambridge University Press 2015; 20–28
- [4] Editorial: Attitudes towards menopause: time for change. *The Lancet*; 2022; 399 : 2243
- [5] UK Parliament : 'Considerable stigma' faced by women going through menopause in the workplace 2022
- [6] Menopause Support – What Is Being Done To Help Women Around The World? Horton International, 2024
- [7] J. Braithwhite. UK Menopause Statistics: attitudes to Menopause at work FORTH, 2023
- [8] Fang Y. et al. Mapping global prevalence of menopausal symptoms among middle-aged women: a systematic review and meta-analysis. *BMC Public Health* 2024; 24:1767
- [9] Avis NE et al. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. *JAMA Intern Med*. 2015; 175:531–539
- [10] Mishra GD et al. Optimising health after early menopause. *Lancet*. 2024; 403: 958–968
- [11] Schoenaker DA et al. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. *Int J Epidemiol*. 2014; 43(5): 1542–62
- [12] Overbeek A et al. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. *Cancer Treat Rev*. 2017; 53:10–24
- [13] Sochocka M et al. Cognitive Decline in Early and Premature Menopause. *Int J Mol Sci*. 2023; 24:6566
- [14] Liu J et al. Early menopause is associated with increased risk of heart failure and atrial fibrillation: A systematic review and meta-analysis. *Maturitas*. 2023; 176:107784;
- [15] Anagnostis P et al. Early menopause is associated with increased risk of arterial hypertension: A systematic review and meta-analysis. *Maturitas*. 2020; 135:74–79
- [16] Huan L et al. Meta-analysis: Early Age at Natural Menopause and Risk for All-Cause and Cardiovascular Mortality. *Biomed Res Int*. 2021; 2021:6636856
- [17] Wan J et al. Incidence of chemotherapy- and chemoradiotherapy-induced amenorrhea in premenopausal women with stage II/III colorectal cancer. *Clin Colorectal Cancer*. 2015; 14:31–4
- [18] Scanlon M et al. Patient Satisfaction with Physician Discussions of Treatment Impact on Fertility, Menopause and Sexual Health among Pre-menopausal Women with Cancer. *J Cancer*. 2012; 3:217–25
- [19] H. C. Moore et al. Predictors of permanent menopause after chemotherapy for early-stage breast cancer in premenopausal women. *JCO*. 2009; 575 (abstract)
- [20] Bedoschi G et al. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. *Future Oncol*. 2016; 22:2333–44
- [21] Hickey M. Managing menopause after cancer. *Lancet*. 2024; 403:984–996
- [22] Harper-Harrison G et al. Hormone Replacement Therapy. [Updated 2024 Oct 6]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK493191/>
- [23] Boardman HM et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. *Cochrane Database Syst Rev*. 2015; 2015(3)
- [24] Farrel E. A tailored approach to manage menopausal syndroms. *Medicine Today* 2023; 24(6 Suppl): 15–18
- [25] Mishra GD et al. Optimising health after early menopause. *Lancet*. 2024; 403(10430):958–968
- [26] Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. *J Steroid Biochem Mol Biol*. 2014; 142:115–20
- [27] Annelies H. Boekhout et al. Schellens, Symptoms and Treatment in Cancer Therapy-Induced Early Menopause, *The Oncologist*, Volume 11, Issue 6, June 2006, Pages 641–654,

[28] The ESHRE Guideline Group on POI, L. Webber, M. Davies, R. Anderson, J. Bartlett, D. Braat, B. Cartwright, R. Cifkova, S. de Muinck Keizer-Schrama, E. Hogervorst, F. Janse, L. Liao, V. Vlaisavljevic, C. Zillikens, N. Vermeulen, ESHRE Guideline: management of women with premature ovarian insufficiency, *Human Reproduction*, Volume 31, Issue 5, May 2016, Pages 926–937

[29] van Driel CM et al. Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis. *BJOG*. 2019. 126(3):330–339

[30] Pyri F et al. The Effect of Mindfulness on Quality of Life among Women with Premature Ovarian Insufficiency: A Randomized Clinical Trial. *J Midlife Health*. 2021. 12(2):116–121

[31] Manson JE et al. The Women's Health Initiative randomized trials and clinical practice: a review. *JAMA*. 2024. 331(20):1748–1760

[32] Chlebowski RT et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. *JAMA*. 2020. 324(4):369–380

[33] J. Kim, P. N. Munster Estrogens and breast cancer *Ann Oncol*. 2025 36(2): 134–148

[34] Oh MR et al. Efficacy of plant-derived dietary supplements in improving overall menopausal symptoms in women: An updated systematic review and meta-analysis. *Phytother Res*. 2024 38(3):1294–1309

[35] Chen MN et al. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. *Climacteric*. 2015. 18(2):260–9

[36] Hauser GA et al. Evaluation der klimakterischen Beschwerden (Menopause Rating Scale [MRS]) [Evaluation of climacteric symptoms (Menopause Rating Scale)]. *Zentralbl Gynakol*. 1994. 116(1):16–23

[37] Chen P. et al. Role of estrogen receptors in health and disease. *Front Endocrinol (Lausanne)*. 2022. 18:13:839005

[38] Tang ZR et al. Estrogen-Receptor Expression and Function in Female Reproductive Disease. *Cells*. 2019. 8(10):1123

[39] Minihane AM. Omega-3 fatty acids, brain health and the menopause. *Post Reprod Health*. 2025. 31(2):97–104

[40] Maria S et al. Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures. *Aging (Albany NY)*. 2017. 9(1):256–285

[41] Kamronrithisorn T, et al. Effect of Vitamin D Supplement on Vulvovaginal Atrophy of the Menopause. *Nutrients*. 2020. 12(9):2876

[42] Rusu ME et al. Investigating the Effects and Mechanisms of Combined Vitamin D and K Supplementation in Postmenopausal Women: An Up-to-Date Comprehensive Review of Clinical Studies. *Nutrients*. 2024. 16(14):2356

[43] Nagy, Mučaji & Grančai, 2017

[44] Monteiro R et al. Effect of hop (*Humulus lupulus L.*) flavonoids on aromatase (estrogen synthase) activity. *J Agric Food Chem*. 2006. 54(8):2938–43

[45] Abourashed EA et al. In vitro binding experiments with a Valerian, hops and their fixed combination extract (Ze91019) to selected central nervous system receptors. *Phytomedicine* 2004. 11(7–8):633–638;

[46] Brattström A. Scientific evidence for a fixed extract combination (Ze 91019) from valerian and hops traditionally used as a sleep-inducing aid. *Wiener Medizinische Wochenschrift* 2007. 157(13–14):367–370

[47] Butterweck V et al. Hypothermic effects of hops are antagonized with the competitive melatonin receptor antagonist luzindole in mice. *Journal of Pharmacy and Pharmacology* 2007. 59(4):549–552

[48] Dietz BM et al. Valerenic extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. *Brain Research Molecular Brain Research* 2005. 138(2):191–197

[49] Franco L et al. The sedative effect of non-alcoholic beer in healthy female nurses. *PLOS ONE* 2012. 7(7):e37290

[50] Savage K et al. GABA-modulating phytomedicines for anxiety: a systematic review of preclinical and clinical evidence. *Phytotherapy Research* 2018. 32(1):3–18

[51] Grundmann O et al. Hypothermic effects of hops could be antagonized with the competitive melatonin receptor antagonist luzindole. *Planta Medica* 2006. 72(11):281).

[52] Benkerrouf AY et al. Humulone modulation of GABA_Areceptors and its role in hops sleep-promoting activity. *Frontiers in Neuroscience* 2020. 14:594708

[53] Ren J et al. Recent progress regarding kaempferol for the treatment of various diseases. *Exp Ther Med*. 2019. 18(4):2759–2776

[54] Schilling T et al. Effects of phytoestrogens and other plant-derived compounds on mesenchymal stem cells, bone maintenance and regeneration. *J Steroid Biochem Mol Biol*. 2014. 139:252–61

[55] Sarfraz A et al. Biochanin A: A novel bioactive multifunctional compound from nature. *Sci Total Environ*. 2020. 722:137907

[56] Seidlová-Wuttke D et al. Pharmacology of *Cimicifuga racemosa* extract BNO 1055 in rats: Bone, fat and uterus. *Maturitas*. 2003. 44:S39–S50

[57] Wuttke W et al. Effects of black cohosh (*Cimicifuga racemosa*) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women. *Menopause*. 2006. 13:185–196

[58] Nappi R.E et al. Efficacy of *Cimicifuga racemosa* on climacteric complaints: A randomized study versus low-dose transdermal estradiol. *Gynecol Endocrinol*. 2005. 20:30–35

[59] Szmyd M et al. The effects of black cohosh on the regulation of estrogen receptor (ER α) and progesterone receptor (PR) in breast cancer cells. *Breast Cancer Targets Ther*. 2018. 10:1–11

[60] Wuttke W et al. The non-estrogenic alternative for the treatment of climacteric complaints: Black cohosh (*Cimicifuga* or *Actaea racemosa*). *J. Steroid Biochem. Mol. Biol.* 2014;139:302–310

[61] Burdette J.E. et al. Black Cohosh Acts as a Mixed Competitive Ligand and Partial Agonist of the Serotonin Receptor. *J. Agric. Food Chem.* 2003; 51:5661–5670

[62] Powell S.L. et al. In Vitro Serotonergic Activity of Black Cohosh and Identification of N^{o} -Methylserotonin as a Potential Active Constituent. *J. Agric. Food Chem.* 2008; 56:11718–11726;

[63] Nikolić D. et al. Metabolism of N^{o} -methylserotonin, a serotonergic constituent of black cohosh (*Cimicifuga racemosa*, L. (Nutt.)), by human liver microsomes. *Biomed. Chromatogr.* 2014; 28:1647–1651

[64] Rhyu M.-R. et al. Black Cohosh (*Actaea racemosa*, *Cimicifuga racemosa*) Behaves as a Mixed Competitive Ligand and Partial Agonist at the Human μ Opiate Receptor. *J. Agric. Food Chem.* 2006; 54:9852–9857

[65] Crone M et al. The antiestrogenic effects of black cohosh on BRCA1 and steroid receptors in breast cancer cells. *Breast Cancer Targets Ther.* 2019; 11:99–110

[66] Poschner S et al. *Actaea racemosa* L. extract inhibits steroid sulfation in human breast cancer cells: Effects on androgen formation. *Phytomedicine.* 2020; 79:153357

[67] Lee Y.S. et al. Actein Isolated from Black Cohosh Promotes the Function of Osteoblastic MC3T3-E1 Cells. *J. Med. Food.* 2014; 17:414–423;

[68] Choi E.M. Deoxyactein stimulates osteoblast function and inhibits bone-resorbing mediators in MC3T3-E1 cells. *J. Appl. Toxicol.* 2013; 33:190–195;

[69] Suh K.S. et al. Actein protects against methylglyoxal-induced oxidative damage in osteoblastic MC3T3-E1 cells. *J. Sci. Food Agric.* 2017; 97:207–214;

[70] Zakir F et al. Design and development of a commercially viable *in situ* nanoemulgel for the treatment of postmenopausal osteoporosis. *Nanomedicine.* 2020; 15:1167–1187

[71] Jiang ZM et al. Hypericum perforatum L. attenuates depression by regulating *Akkermansia muciniphila*, tryptophan metabolism and *NF κ B-NLRP2-Caspase1-IL1 β* pathway. *Phytomedicine.* 2024; 132:155847

[72] Laniewski P, Herbst-Kralovetz MM. Connecting microbiome and menopause for healthy ageing. *Nat Microbiol.* 2022; 7(3):354–358

[73] Hidalgo LA et al. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. *Gynecol Endocrinol.* 2005; 21(5):257–64

[74] Kanadys W et al. Evaluation of Clinical Meaningfulness of Red Clover (*Trifolium pratense* L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Nutrients.* 2021; 11;13(4):1258

[75] Lipovac M et al. The effect of red clover isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal women. *Gynecol Endocrinol.* 2012; 28(3):203–7

[76] Shakeri F et al. Effectiveness of red clover in alleviating menopausal symptoms: a 12-week randomized, controlled trial. *Climacteric.* 2015; 18(4):568–73

[77] Kupfersztain C et al. The immediate effect of natural plant extract, *Angelica sinensis* and *Matricaria chamomilla* (Climex) for the treatment of hot flushes during menopause. A preliminary report. *Clin Exp Obstet Gynecol.* 2003; 30(4):203–6

[78] Naseri R et al. Comparison of *Vitex agnus-castus* Extracts with Placebo in Reducing Menopausal Symptoms: A Randomized Double-Blind Study. *Korean J Fam Med.* 2019; 40(6):362–367

[79] van Die MD et al. *Vitex agnus-castus* (Chaste-Tree/Berry) in the treatment of menopause-related complaints. *J Altern Complement Med.* 2009; 15(8):853–62

[80] Maffei S et al. Long-term effects of a combination of isoflavones, agnus castus and magnolia extracts on climacteric symptoms and cardiometabolic risk profile in postmenopausal women. *Gynecol Endocrinol.* 2022; 38(4):339–344

[81] Shrivastava R et al. Effects of Flaxseed on Perimenopausal Symptoms: Findings From a Single-Blind, Randomized, Placebo-Controlled Study. *Cureus.* 2024; 3;16(9):e68534

[82] Cetisli NE et al. The effects of flaxseed on menopausal symptoms and quality of life. *Holist Nurs Pract.* 2015; 29(3):151–7

[83] Meissner HO et al. Hormone-Balancing Effect of Pre-Gelatinized Organic Maca (*Lepidium peruvianum Chacon*): (II) Physiological and Symptomatic Responses of Early-Postmenopausal Women to Standardized doses of Maca in Double Blind, Randomized, Placebo-Controlled, Multi-Centre Clinical Study. *Int J Biomed Sci.* 2006; 2(4):360–74

[84] Brooks NA et al. Beneficial effects of *Lepidium meyenii* (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content. *Menopause.* 2008; 15(6):1157–62

[85] Stojanovska L et al. Maca reduces blood pressure and depression, in a pilot study in postmenopausal women. *Climacteric.* 2015; 18(1):69–78

[86] Wilfried D et al. Effectiveness of Menosan® *Salvia officinalis* in the treatment of a wide spectrum of menopausal complaints. A double-blind, randomized, placebo-controlled, clinical trial. *Heliyon.* 2021; 7(2):e05910

[87] Dadfar F, Bamdad K. The effect of *Salvia officinalis* extract on the menopausal symptoms in postmenopausal women: An RCT. *Int J Reprod Biomed.* 2019; 17(4):287–92

[88] Zeidabadi A et al. The effect of *Salvia officinalis* extract on symptoms of flushing, night sweat, sleep disorders, and score of forgetfulness in postmenopausal women. *J Family Med Prim Care.* 2020; 9(2):1086–1092

[89] Štulíková K et al. Therapeutic Perspectives of 8-Prenylharingenin, a Potent Phytoestrogen from Hops. *Molecules*. 2018; 23(3):660

[90] Simons R et al. Prenylated isoflavonoids from plants as selective estrogen receptor modulators (phytoSERMs). *Food Funct*. 2012; 3(8):810–27

[91] Heyerick A et al. A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. *Maturitas*. 2006; 54(2):164–75

[92] Castelo-Branco C et al. Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence. *Climacteric*. 2021; 24(2):109–119

[93] Eatemadnia A et al. The effect of *Hypericum perforatum* on postmenopausal symptoms and depression: A randomized controlled trial. *Complement Ther Med*. 2019; 45:109–113

[94] Fahami F et al. A comparative study on the effects of *Hypericum Perforatum* and passion flower on the menopausal symptoms of women referring to Isfahan city health care centers. *Iran J Nurs Midwifery Res*. 2010; 15(4):202–7

[95] van Die MD et al. Effects of a combination of *Hypericum perforatum* and *Vitex agnus-castus* on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis. *J Altern Complement Med*. 2009; 15(9):1045–8

[96] Al-Akoum M et al. Effects of *Hypericum perforatum* (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. *Menopause*. 2009; 16(2):307–14

[97] Perna S et al. Multidimensional Effects of Soy Isoflavone by Food or Supplements in Menopause Women: a Systematic Review and Bibliometric Analysis. *Nat Prod Commun*. 2016; 11(11):1733–1740

[98] Duffy R et al. Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones. *Pharmacol Biochem Behav*. 2003; 75(3):721–9

[99] Nahas EA et al. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. *Maturitas*. 2007; 58(3):249–58

[100] Hachul H et al., Brandão LC, D'Almeida V, Bittencourt LR, Baracat EC, Tufik S. Isoflavones decrease insomnia in postmenopause. *Menopause*. 2011; 18(2):178–84

[101] Choquette S et al. Effects of soya isoflavones and exercise on body composition and clinical risk factors of cardiovascular diseases in overweight postmenopausal women: a 6-month double-blind controlled trial. *Br J Nutr*. 2011; 105(8):1199–209

[102] Riesco E et al. Effect of exercise combined with phytoestrogens on quality of life in postmenopausal women. *Climacteric*. 2011; 14(5):573–80

[103] Carmignani LO et al. Effects of a soy-based dietary supplement compared with low-dose hormone therapy on the urogenital system: a randomized, double-blind, controlled clinical trial. *Menopause*. 2015; 22(7):741–9

[104] Purzand B et al. The comparison of the effect of soybean and fish oil on supplementation on menopausal symptoms in postmenopausal women: A randomized, double-blind, placebo-controlled trial. *Complement Ther Clin Pract*. 2020; 41:101239

[105] Frei-Kleiner S et al. *Cimicifuga racemosa* dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. *Maturitas*. 2005; 51(4):397–404

[106] Jiang K et al. Black cohosh improves objective sleep in postmenopausal women with sleep disturbance. *Climacteric*. 2015; 8(4):559–67

[107] Pkhaladze L et al. Is More Effective in Combination with *Rhodiola rosea* L. for Relief of Menopausal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study. *Pharmaceuticals (Basel)*. 2020; 13(5):102